ValuEngine Downgrades ESSA Pharma (NASDAQ:EPIX) to Hold

Share on StockTwits

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Tuesday, ValuEngine reports.

EPIX has been the topic of several other reports. HC Wainwright reissued a “buy” rating on shares of ESSA Pharma in a research report on Friday, May 17th. Zacks Investment Research raised shares of ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Wednesday, May 22nd.

Shares of EPIX traded up $0.05 during mid-day trading on Tuesday, hitting $2.82. The company had a trading volume of 11,180 shares, compared to its average volume of 16,424. The business’s 50-day simple moving average is $2.21 and its 200-day simple moving average is $2.63. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 2.27. ESSA Pharma has a 1-year low of $1.41 and a 1-year high of $4.50. The stock has a market cap of $22.38 million, a PE ratio of -1.11 and a beta of 1.85.

ESSA Pharma Company Profile

ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Further Reading: What is a Stop Order?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Scientific Games  Rating Lowered to Sell at ValuEngine
Scientific Games Rating Lowered to Sell at ValuEngine
Wingstop  Downgraded by BidaskClub
Wingstop Downgraded by BidaskClub
Encompass Health  Research Coverage Started at Deutsche Bank
Encompass Health Research Coverage Started at Deutsche Bank
Critical Contrast: PlusTherapeuticsInc   .  vs. Stryker
Critical Contrast: PlusTherapeuticsInc . vs. Stryker
Contrasting Sito Mobile  and Invictus Financial
Contrasting Sito Mobile and Invictus Financial
Pinnacle Financial Partners  Rating Reiterated by Stephens
Pinnacle Financial Partners Rating Reiterated by Stephens


 
© 2006-2019 Zolmax.